Oral Etoposide and Carboplatin: Effective Therapy for Elderly Patients with Small Cell Lung Cancer

Purpose Elderly patients with small cell lung cancer (SCLC) and/or those with comorbid conditions are frequently not considered candidates for standard combination chemotherapy. An active, but less toxic regimen is needed for this group of patients. Patients and Methods Forty-seven elderly (>65 years) or medically unfit patients with SCLC were treated with oral etoposide 100 mg/m2 × 7 days and carboplatin 150 mg/m2 day 1. Treatment was given every 3–4 weeks for six cycles in responding patients. Patients responding to the chemotherapy regimen were also treated with prophylactic cranial irradiation, and limited-stage patients received thoracic radiotherapy. The study population included 36 extensive-stage patients and 11 limited-disease patients with renal or cardiac disease that precluded standard chemotherapy. The median age of the study population was 69 years (range: 47–84). Results Nine of 47 patients were inevaluable for response, including four patients who succumbed to sepsis. Of the 38 patients evaluable for response, 71% responded (95% CI: 56–86%) (88% LD; 67% ED) with a complete response in 29% of patients (50% LD; 23% ED). Based on an analysis of intent to treat, the overall response rate was 60% and the median survival time of the whole group was 46 weeks (LD, 59 weeks; ED, 45 weeks). Treatment was generally well tolerated. Neutropenia was the dose-limiting toxicity; the median nadir granulocyte count was 1.04 × 109/L (range: 0–8.2). Conclusion We conclude that this regimen can provide palliation to SCLC patients who might not otherwise be considered for systemic chemotherapy.